AstraZeneca's results signal more good vaccine news — but efficacy is only the beginning of the story
ShutterstockAstraZeneca has become the latest pharmaceutical company to reveal promising results in clinical trials, for its viral vector vaccine developed with the University of Oxford.
In a group given two full doses of the vaccine at least one month apart, the vaccine demonstrated 62% efficacy at preventing COVID. Interestingly, in another group...
